EVOTEC’S LICENSE AGREEMENT GENOME EDITING TECHNOLOGY
CRISPR-CAS9 ON
DGAP-News: Evotec AG / Key word (s): Miscellaneous
EVOTEC’S LICENSE AGREEMENT GENOME EDITING TECHNOLOGY CRISPR-CAS9
A
The issuer 06.07.2016 / 07:29 For the content of this announcement
. Responsible
Hamburg 06 July 2016: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX, ISIN: DE0005664809) today announced that the
Company a non-exclusive license agreement with the Broad
Institute of MIT and Harvard regarding the Genome
Editing technology CRISPR-Cas9 has been received.
As a result of the license agreement obtained Evotec access to intellectual
Property of the CRISPR-Cas9 technology and is the technology in their
Discovery offering and its research and
Development activities to integrate, especially in developing
of research methods and target identification and to
Expand their target deconvolution platform
(Post-phenotypic screen).
Under the agreement Evotec receives nonexclusive
Access to market-leading genome editing technology.
Dr. Mario Polywka, Chief Operating Officer of Evotec,
commented, “The opportunity to work with Evotec comprehensive
Expertise in the area stem cells, the market CRISPR-Cas9
offer underscores our ongoing approach, modern
use technology to bring our partners added value
and to enhance the research and development pipeline. “
ABOUT THE CRISPR-CAS9 SYSTEM CRISPR (Clustered Regularly
Inter Spaced Short Palindromic repeats) is a naturally
occurring bacterial immune system. Scientists set this
System as genome editing tool for mammalian cells. The Genome
Editing technology enables scientists to the action
to achieve on certain genes in order to mutate these, a knock-out
or their expression increase in living cells. By
Application of CRISPR-Cas9 technology can provide valuable insight into
the function of these genes in the onset of diseases and
its progress can be obtained.
ABOUT EVOTEC AG
Evotec is a drug discovery and development, which in
Research and development alliances partnerships with leading
Pharmaceutical and biotechnology companies, academic institutions,
Patient organizations and venture capital companies innovative
Approaches to the development of new pharmaceutical products quickly
drives. We operate worldwide and provide our customers
high-quality, independent and integrated solutions
Area of drug discovery. We cover all activities
from target to clinical development from to the needs of
Industry to innovation and efficiency in drug discovery
to meet (EVT Execute). By merging
world-class scientists, advanced technology and
extensive experience and expertise in key
Therapeutic areas including neuroscience, diabetes
and diabetes complications, pain and inflammatory diseases,
Oncology and infectious diseases Evotec today is unique
positioned. On this basis, Evotec has its pipeline
consisting of more than 70 partnered programs in clinical,
preclinical and structured research phase (EVT Innovate). Evotec
has long-term discovery alliances with partners such as Bayer,
CHDI, Sanofi or UCB together. Moreover, has the
Company Development Partnerships u. A. With Janssen
Pharmaceuticals in the field of Alzheimer’s disease, with
Sanofi in diabetes as well as with Pfizer in the field
Organ fibrosis. For more information, visit our website.
contains www.evotec.com.
FORWARD-LOOKING STATEMENTS This press release
certain forward-looking statements that involve risks and uncertainties
include. Such forward-looking statements are neither
Promises nor guarantees, but are subject to
numerous risks and uncertainties, many of which our
Revoke Control, and may cause the
differ actual results of those who in
These forward-looking statements should be considered. We
expressly disclaim any obligation to update forward-looking
Statements regarding changed expectations or
any change in events, conditions or circumstances on which any
These statements are subject to update publicly or
. Revise
Contact Evotec AG: Gabriele Hansen, VP Corporate Communications & amp;
Investor Relations, Tel .: +49. (0) 40.56081-255,
gabriele.hansen@evotec.com
07.06.2016 Release of a Corporate News / Financial news
transmitted by DGAP – a service of EQS Group AG. For the
Content of this announcement is the issuer / publisher responsible.
DGAP Distribution Services include Regulatory
Announcements, Financial / Corporate News and
Press Releases. Media archive at http://www.dgap.de
Language: German
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0) 40 560 81-0
Fax: +49 (0) 40 560 81-222
Email: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Exchanges: Regulated Market in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Dusseldorf, Hamburg, Hanover, Munich,
Stuttgart; EUREX
End of News DGAP News-Service
478 575 07/06/2016
ISIN DE0005664809
AXC0028 2016-07-06 / 07: 29
No comments:
Post a Comment